Various problems of clinical psychopharmacology (pharmacokinetics and drug interactions)
Kanarkowski, R.; Targońska, A.
Psychiatria Polska 12(2): 263-272
1978
ISSN/ISBN: 0033-2674 PMID: 662988 Document Number: 125254
Document emailed within 1 workday
Related Documents
Linares, O.A.; Fudin, J.; Boston, R.C.; Daly, A.L. 2015: Integrating Clinical Pharmacokinetics, Pharmacogenetics, and Quantitative Cytochrome P450 Polymorphic Gene Drug-Drug Interactions (DDIs) Pain Physician 18(3): E439-E441Staiger, C. 1982: Oral contraceptives. Clinical pharmacology, pharmacokinetics and drug interactions Münchener Medizinische Wochenschrift 124(20): 495-498
Müller-Oerlinghausen, B. 1978: Ethical problems in clinical psychopharmacology International Journal of Clinical Pharmacology and Biopharmacy 16(10): 443-450
Sellers, E.M. 1984: Ethanol-psychotropic drug interactions: pharmacokinetics Psychopharmacology Bulletin 20(3): 497-499
Sawada, Y.; Ohtani, H. 2001: Pharmacokinetics and drug interactions of antidepressive agents Nihon Rinsho. Japanese Journal of Clinical Medicine 59(8): 1539-1545
Furue, H. 1986: Application and problems of combination drug therapy--drug interactions of antineoplastic agents and antibiotics Nihon Rinsho. Japanese Journal of Clinical Medicine 44(4): 942-946
Gladtke, E. 1981: Current problems in drug therapy in children. Drug interactions, age-dependent changes in pharmacokinetic data, recommendations for dosage Die Medizinische Welt 32(7): 219-224
Crismon, M.L. 1998: Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease PharmacoTherapy 18(2 Part 2): 47-54; Discussion: 79-82
Kohl, C.; Steinkellner, M. 2000: Prediction of pharmacokinetic drug/drug interactions from in vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants Drug Metabolism and Disposition: the Biological Fate of Chemicals 28(2): 161-168
Patat, A. 1995: Drug interactions: methological problems Therapie 50(3): 203-214
Fürtig, W.; Heydel, E.; Box, A. 1984: Pharmacokinetic mechanisms of drug interactions. 1. General problems Die Pharmazie 39(1): 71-73
Estler, C.J. 1984: Drug interactions of central nervous system active drugs. 3: Drug interactions of anticonvulsants and antiparkinson agents Fortschritte der Medizin 102(6): 129-132
Levy, R.H.; Moreland, T.A. 1984: Clinical pharmacokinetics of sodium valproate, carbamazepine and phenytoin. Level-dose ration and interactions Schweizerische Rundschau für Medizin Praxis 73(6): 159-163
Timour, Q.; Freysz, M.; Couzon, P.; Loufoua, J.; Bertrix, L.; Gerentes, I.; Faucon, G. 1990: Possible role of drug interactions in bupivacaine-induced problems related to intraventricular conduction disorders Regional Anesthesia 15(4): 180-185
Kapor, G. 1971: Problems of current psychopharmacology Vojnosanitetski Pregled 28(11): 578-581
Rodríguez Terol, A.; Santos Ramos, B.; Caraballo Camacho, M.; Ollero Baturone, M. 2008: Clinical significance of drug interactions Medicina clinica 130(19): 758-9; author reply 759
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Cockburn, I. 1986: Cyclosporine A: a clinical evaluation of drug interactions Transplantation Proceedings 18(6 Suppl 5: 50-55
Paxton, J.W. 1981: Therapeutic drug monitoring and clinical pharmacokinetics Australian and New Zealand Journal of Medicine 11(5): 558-561
Filipczyk-Cisarz, E. 2000: Clinical implications of undesirable consequences of antineoplastic drug interactions Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 9(51): 632-633